Halozyme Therapeutics reported $198M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 5.69B 6B Sep/2026
Baxter International USD 6.5B 3.82B Sep/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
DBV Technologies USD 64.8M 16.9M Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
MannKind USD 104.44M 5.77M Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Pfizer USD 89B 3.81B Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 6.28B 124.3M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025